Form 4: Bioxytran CFO Ola Soderquist Reports Transactions Involving Preferred and Common Stock

Ola Soderquist, CFO of Bioxytran, Inc., reports acquisition and disposal of preferred and common stock related to the sale of NDPD Pharma and a stock exchange.

Summary

• Ola Soderquist, the CFO of Bioxytran, Inc. (BIXT), filed a Form 4 detailing changes in beneficial ownership.
• On October 25, 2024, Soderquist acquired 10,197,611 shares of preferred stock at $0.545 per share as payment for the sale of NDPD Pharma to Bioxytran.
• On the same day, Soderquist disposed of 100,000 shares of preferred stock at $0.005 per share and acquired 500,000 shares of common stock at $0.001 per share through a 1:5 exchange of preferred stock into common stock.
• Following these transactions, Soderquist beneficially owns 14,004,671 shares of preferred stock and 500,000 shares of common stock.

Sentiment

Score: 6

Explanation: The sentiment is neutral. The transactions are related to the acquisition of NDPD Pharma and a routine stock exchange. The CFO's increased stake could be seen as a positive signal.

Positives

• The acquisition of preferred stock by the CFO indicates confidence in the company's prospects following the NDPD Pharma acquisition.

Risks

• The disposal of preferred stock, even if part of a planned exchange, could be perceived negatively by some investors.

Industry Context

Form 4 filings are a routine part of corporate governance, providing transparency into the transactions of company insiders. The sale of NDPD Pharma is a material event for Bioxytran.

Stakeholder Impact

• Shareholders may be interested in the CFO's transactions as an indicator of company performance and future prospects.

Key Dates

Keywords

Bioxytran, BIXT, Form 4, Ola Soderquist, CFO, Beneficial Ownership, Preferred Stock, Common Stock, NDPD Pharma, Acquisition, Disposal, Stock Exchange